You are here

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

TitleBrief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
Publication TypeJournal Article
Year of Publication2015
AuthorsWalmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M-, J Kilby M, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K
JournalJ Acquir Immune Defic Syndr
Volume70
Issue5
Pagination515-9
Date Published2015 Dec 15
ISSN1944-7884
KeywordsAnti-HIV Agents, Dideoxynucleosides, Double-Blind Method, Drug Administration Schedule, Drug Combinations, Drug Therapy, Combination, Heterocyclic Compounds, 3-Ring, HIV Infections, HIV-1, Humans, Lamivudine
Abstract

The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of 833 randomized participants, 71% in the dolutegravir + abacavir/lamivudine arm and 63% in the efavirenz/tenofovir/emtricitabine arm maintained viral loads of <50 copies per milliliter through W144 (P = 0.01). Superior efficacy was primarily driven by fewer discontinuations due to adverse events in the dolutegravir + abacavir/lamivudine arm [dolutegravir + abacavir/lamivudine arm, 16 (4%); efavirenz/tenofovir/emtricitabine arm, 58 (14%)] through W144 [corrected]. No treatment-emergent integrase or nucleoside resistance was observed in dolutegravir + abacavir/lamivudine recipients through W144.

DOI10.1097/QAI.0000000000000790
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID26262777
PubMed Central IDPMC4645960